Show simple item record

dc.contributor.supervisor Wigle, Jeffrey (Biochemistry and Medical Genetics) en_US
dc.contributor.author Jahan, Fahmida
dc.date.accessioned 2016-01-15T15:38:22Z
dc.date.available 2016-01-15T15:38:22Z
dc.date.issued 2014-January en_US
dc.date.issued 2015-April en_US
dc.date.issued 2014-April en_US
dc.identifier.citation Cunnington, R.H., et al., The Ski-Zeb2-Meox2 pathway provides a novel mechanism for regulation of the cardiac myofibroblast phenotype. J Cell Sci, 2014. 127(Pt 1): p. 40-9. en_US
dc.identifier.citation Jahan, F., et al., Control of Cardiac Fibroblast Phenotype by the Meox2/Zeb2 Signalling Switch. The FASEB Journal,2014. vol. 28 no. 1 Supplement LB47 en_US
dc.identifier.citation Jahan, F., et al., Zeb2: A novel regulator of cardiac fibroblast to myofibroblast transition. The FASEB Journal, 2015. vol. 29 no. 1 Supplement 556.1 en_US
dc.identifier.uri http://hdl.handle.net/1993/31090
dc.description.abstract Cardiac fibroblast to myofibroblast phenoconversion is a critical step during the development of cardiac fibrosis. Myofibroblasts chronically remodel extracellular matrix that results in myocardial stiffening, cardiac dysfunction and eventually heart failure. Previously we showed that Meox2, a homeobox transcription factor, can inhibit myofibroblast phenoconversion. Here we show that Zeb2, a repressor of Meox2, plays a crucial role during this phenoconversion process. Zeb2 overexpression significantly upregulates the expression of three key myofibroblast markers: α-SMA, SMemb and ED-A fibronectin in primary rat cardiac myofibroblast. We show that Zeb2 is highly expressed in myofibroblast nuclei whereas it is minimally expressed in fibroblast nuclei. Zeb2 overexpression in myofibroblasts results in a less migratory and more contractile mature myofibroblast phenotype. Moreover, Zeb2 overexpression represses Meox2 expression in endothelial cells. Thus, the current study enhances our understanding of the mechanism behind myofibroblast phenoconversion and provides a basis for developing Zeb2-based novel anti-fibrotic drug in the future. en_US
dc.publisher Company of biologists Ltd. en_US
dc.publisher Federation of American Societies for Experimental Biology en_US
dc.rights info:eu-repo/semantics/openAccess
dc.subject Zeb2 en_US
dc.subject Meox2 en_US
dc.subject Cardiac fibroblast en_US
dc.subject Myofibroblast en_US
dc.subject Phenoconversion en_US
dc.subject Cardiac fibrosis en_US
dc.title Zeb2: A novel regulator of cardiac fibroblast to myofibroblast transition en_US
dc.type info:eu-repo/semantics/masterThesis
dc.type master thesis en_US
dc.degree.discipline Biochemistry and Medical Genetics en_US
dc.contributor.examiningcommittee Nachtigal, Mark (Biochemistry and Medical Genetics) Dixon, Ian (Physiology and Pathophysiology) en_US
dc.degree.level Master of Science (M.Sc.) en_US
dc.description.note February 2016 en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

View Statistics